Clinical Trials: General Audit Findings in Clinical Trials

What Are the Most Common Regulatory Audit Findings in Clinical Trials?

Posted on digi By digi

Regulatory audits are designed to safeguard both patient safety and data integrity in clinical trials. Inspections carried out by authorities such as the FDA, EMA, MHRA, and WHO assess whether trials adhere to global standards like ICH-GCP. When deficiencies are identified, they are recorded as audit findings, which may range from minor observations to critical violations that threaten trial validity.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

How Regulatory Authorities Identify Audit Findings in Clinical Trial Inspections

Posted on digi By digi

Regulatory authorities play a vital role in ensuring that clinical trials adhere to ethical and scientific standards. Inspections conducted by the FDA, EMA, MHRA, and other agencies are not merely routine checks but structured evaluations of compliance with international standards such as ICH-GCP and regional legislations like FDA 21 CFR. Their objective is to identify deficiencies—known as audit findings—that may compromise participant safety or data integrity.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

Top FDA Audit Findings in Clinical Trials and How to Avoid Them

Posted on digi By digi

The U.S. Food and Drug Administration (FDA) is among the most influential regulatory authorities in the world, and its inspections of clinical trials carry significant weight. Findings from an FDA audit not only impact individual trials but can also influence the credibility of a sponsor’s overall research program. Audit deficiencies may result in Form 483 observations, warning letters, or in severe cases, clinical holds and rejection of a marketing application.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

EMA Clinical Trial Audit Findings: Lessons for Sponsors and Sites

Posted on digi By digi

The European Medicines Agency (EMA), together with national competent authorities (NCAs), plays a central role in regulating clinical trials across the European Union. Since the implementation of the EU Clinical Trial Regulation (Regulation EU No. 536/2014), regulatory scrutiny has intensified, particularly around transparency, patient safety, and data integrity. Inspections conducted by EMA and NCAs assess whether trials comply with ICH-GCP standards and regional requirements.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

ICH GCP Audit Findings: Frequent Issues Across Global Trials

Posted on digi By digi

The International Council for Harmonisation (ICH) introduced Good Clinical Practice (GCP) guidelines to harmonize ethical and scientific standards for clinical trials globally. The most widely applied guideline—ICH E6(R2), and the evolving E6(R3)—sets expectations for sponsors, investigators, and CROs regarding the conduct, monitoring, recording, and reporting of trials.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

Clinical Trial Inspection Findings: What Sponsors Need to Know

Posted on digi By digi

Clinical trial inspections are critical mechanisms used by regulatory authorities such as the FDA, EMA, MHRA, and PMDA to evaluate compliance with ICH GCP, regional laws, and ethical standards. Findings from these inspections directly impact a sponsor’s ability to secure regulatory approvals and maintain credibility. For sponsors, inspection readiness is not a one-time exercise but a continuous obligation throughout the lifecycle of a clinical trial.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

Audit Findings in Phase I vs. Phase III Clinical Trials – Key Differences

Posted on digi By digi

Clinical trials progress through distinct phases, each with unique objectives, designs, and regulatory scrutiny. Phase I trials typically involve a small number of healthy volunteers or patients to evaluate safety, tolerability, and pharmacokinetics. In contrast, Phase III trials enroll large patient populations to confirm efficacy and monitor adverse events at scale. Regulatory authorities such as the FDA, EMA, and MHRA adjust their inspection strategies depending on the trial phase, leading to different patterns of audit findings.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

Common Regulatory Audit Observations During Multicenter Trials

Posted on digi By digi

Multicenter clinical trials offer sponsors the ability to enroll large, diverse patient populations across different geographies, enhancing the statistical power and generalizability of study results. However, the complexity of coordinating numerous sites introduces significant compliance risks. Regulatory authorities such as the FDA, EMA, and MHRA consistently report higher rates of audit findings in multicenter studies compared to single-site trials.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

Recent Trends in Regulatory Audit Findings in Global Clinical Trials

Posted on digi By digi

Over the past decade, clinical trial inspections have evolved significantly as regulatory agencies adapt to new challenges, technologies, and trial designs. The FDA, EMA, MHRA, and PMDA have emphasized transparency, data integrity, and patient safety as core priorities. More recently, the COVID-19 pandemic and the rise of decentralized clinical trials (DCTs) have reshaped inspection practices, resulting in new patterns of audit findings.

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings

Case Studies of High-Impact Clinical Trial Audit Findings

Posted on digi By digi

Regulatory audits often uncover deficiencies that shape the future of clinical trial oversight. High-impact findings not only affect individual trials but also set precedents for regulatory expectations. By analyzing case studies of significant audit findings from agencies such as the FDA, EMA, and MHRA, sponsors and sites can identify recurring pitfalls, understand root causes, and implement effective Corrective and Preventive Actions (CAPA).

Click to read the full article.

General Audit Findings in Clinical Trials, Regulatory Audit Findings